Edoxaban - Daiichi Sankyo Company
Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSALatest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Kyushu University
- Class Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Phase III Myocardial infarction; Pulmonary hypertension
- No development reported Venous thrombosis
Most Recent Events
- 13 Dec 2024 No development reported - Phase-III for Venous thromboembolism (In adolescents, In children) in Bulgaria (PO)
- 13 Dec 2024 No development reported - Phase-III for Venous thromboembolism (In children, In adolescents) in Guatemala (PO)
- 13 Dec 2024 No development reported - Phase-III for Venous thromboembolism (In children, In adolescents) in Kenya (PO)